AAPL303.42-5.49 (-1.78%) ▼|ABBV245.10-5.84 (-2.33%) ▼|ABT107.12+1.42 (+1.34%) ▲|ACN165.76-0.16 (-0.10%) ▼|ADBE251.34+0.93 (+0.37%) ▲|AMAT518.21+10.54 (+2.08%) ▲|AMD484.64+8.49 (+1.78%) ▲|AMGN378.87-6.29 (-1.63%) ▼|AMT173.00-0.36 (-0.21%) ▼|AMZN284.02+12.44 (+4.58%) ▲|AVGO392.23+2.95 (+0.76%) ▲|AXP344.72+8.47 (+2.52%) ▲|BA233.49+17.35 (+8.03%) ▲|BAC62.48+0.53 (+0.86%) ▲|BKNG192.71-0.19 (-0.10%) ▼|BLK1,126.63+36.24 (+3.32%) ▲|BMY65.47+0.16 (+0.25%) ▲|BNY156.20-0.13 (-0.08%) ▼|BRK-B513.14+1.60 (+0.31%) ▲|C133.57+1.79 (+1.36%) ▲|CAT830.03+15.22 (+1.87%) ▲|CL89.88-1.42 (-1.56%) ▼|CMCSA24.56+0.60 (+2.50%) ▲|COF217.68+8.67 (+4.15%) ▲|COP119.16-1.32 (-1.10%) ▼|COST954.08+2.19 (+0.23%) ▲|CRM185.95+1.93 (+1.05%) ▲|CSCO115.86-0.13 (-0.11%) ▼|CVS105.37+0.94 (+0.90%) ▲|CVX193.18-3.65 (-1.85%) ▼|DE605.06+12.39 (+2.09%) ▲|DHR197.50+2.52 (+1.29%) ▲|DIS98.14+1.95 (+2.03%) ▲|DUK124.28-1.15 (-0.92%) ▼|EMR154.85+5.03 (+3.36%) ▲|FDX309.24+1.84 (+0.60%) ▲|GD382.43-0.99 (-0.26%) ▼|GE368.93+8.86 (+2.46%) ▲|GEV1,006.76+16.47 (+1.66%) ▲|GILD131.15+0.94 (+0.72%) ▲|GM87.68-1.18 (-1.33%) ▼|GOOG372.47+15.82 (+4.44%) ▲|GOOGL373.51+17.38 (+4.88%) ▲|GS1,027.06+8.68 (+0.85%) ▲|HD340.02+8.06 (+2.43%) ▲|HON246.77+3.72 (+1.53%) ▲|IBM226.31+2.66 (+1.19%) ▲|INTC91.00+0.80 (+0.89%) ▲|INTU318.39+2.32 (+0.73%) ▲|ISRG375.41+22.08 (+6.25%) ▲|JNJ254.41-1.94 (-0.76%) ▼|JPM352.64+0.85 (+0.24%) ▲|KO86.86-0.73 (-0.83%) ▼|LIN480.46+2.08 (+0.43%) ▲|LLY1,121.36-27.48 (-2.39%) ▼|LMT586.29+3.55 (+0.61%) ▲|LOW212.06+4.25 (+2.05%) ▲|LRCX294.61+1.59 (+0.54%) ▲|MA570.97-2.13 (-0.37%) ▼|MCD265.23-5.41 (-2.00%) ▼|MDLZ61.73-0.58 (-0.93%) ▼|MDT86.68+1.29 (+1.51%) ▲|META590.24+33.53 (+6.02%) ▲|MMM177.23+0.95 (+0.54%) ▲|MO68.26-0.07 (-0.10%) ▼|MRK127.77-2.43 (-1.87%) ▼|MS211.23+0.81 (+0.38%) ▲|MSFT487.65+22.93 (+4.93%) ▲|MU829.50+6.47 (+0.79%) ▲|NEE86.55-0.37 (-0.43%) ▼|NFLX73.33+1.62 (+2.26%) ▲|NKE42.64+0.93 (+2.23%) ▲|NOW114.19+2.96 (+2.66%) ▲|NVDA206.64+5.89 (+2.93%) ▲|ORCL141.85+11.98 (+9.22%) ▲|PEP139.63+0.07 (+0.05%) ▲|PFE25.03+0.02 (+0.08%) ▲|PG144.97+0.48 (+0.33%) ▲|PLTR125.65+2.59 (+2.10%) ▲|PM187.41-3.41 (-1.79%) ▼|QCOM151.57+3.96 (+2.68%) ▲|RTX216.65+1.43 (+0.66%) ▲|SBUX103.37-1.88 (-1.79%) ▼|SCHW105.87+0.63 (+0.60%) ▲|SO92.94-1.60 (-1.69%) ▼|SPG229.16-0.21 (-0.09%) ▼|T23.59+0.34 (+1.46%) ▲|TMO574.03-0.27 (-0.05%) ▼|TMUS177.09+4.38 (+2.54%) ▲|TSLA322.08+10.87 (+3.49%) ▲|TXN269.04-6.70 (-2.43%) ▼|UBER71.61+1.25 (+1.78%) ▲|UNH415.36+0.96 (+0.23%) ▲|UNP291.23-0.90 (-0.31%) ▼|UPS106.87+2.65 (+2.54%) ▲|USB63.94+0.93 (+1.48%) ▲|V365.67-0.46 (-0.13%) ▼|VZ47.36+0.55 (+1.18%) ▲|WFC87.89+1.44 (+1.67%) ▲|WMT110.71-0.49 (-0.44%) ▼|XOM155.06-0.38 (-0.24%) ▼|AAPL303.42-5.49 (-1.78%) ▼|ABBV245.10-5.84 (-2.33%) ▼|ABT107.12+1.42 (+1.34%) ▲|ACN165.76-0.16 (-0.10%) ▼|ADBE251.34+0.93 (+0.37%) ▲|AMAT518.21+10.54 (+2.08%) ▲|AMD484.64+8.49 (+1.78%) ▲|AMGN378.87-6.29 (-1.63%) ▼|AMT173.00-0.36 (-0.21%) ▼|AMZN284.02+12.44 (+4.58%) ▲|AVGO392.23+2.95 (+0.76%) ▲|AXP344.72+8.47 (+2.52%) ▲|BA233.49+17.35 (+8.03%) ▲|BAC62.48+0.53 (+0.86%) ▲|BKNG192.71-0.19 (-0.10%) ▼|BLK1,126.63+36.24 (+3.32%) ▲|BMY65.47+0.16 (+0.25%) ▲|BNY156.20-0.13 (-0.08%) ▼|BRK-B513.14+1.60 (+0.31%) ▲|C133.57+1.79 (+1.36%) ▲|CAT830.03+15.22 (+1.87%) ▲|CL89.88-1.42 (-1.56%) ▼|CMCSA24.56+0.60 (+2.50%) ▲|COF217.68+8.67 (+4.15%) ▲|COP119.16-1.32 (-1.10%) ▼|COST954.08+2.19 (+0.23%) ▲|CRM185.95+1.93 (+1.05%) ▲|CSCO115.86-0.13 (-0.11%) ▼|CVS105.37+0.94 (+0.90%) ▲|CVX193.18-3.65 (-1.85%) ▼|DE605.06+12.39 (+2.09%) ▲|DHR197.50+2.52 (+1.29%) ▲|DIS98.14+1.95 (+2.03%) ▲|DUK124.28-1.15 (-0.92%) ▼|EMR154.85+5.03 (+3.36%) ▲|FDX309.24+1.84 (+0.60%) ▲|GD382.43-0.99 (-0.26%) ▼|GE368.93+8.86 (+2.46%) ▲|GEV1,006.76+16.47 (+1.66%) ▲|GILD131.15+0.94 (+0.72%) ▲|GM87.68-1.18 (-1.33%) ▼|GOOG372.47+15.82 (+4.44%) ▲|GOOGL373.51+17.38 (+4.88%) ▲|GS1,027.06+8.68 (+0.85%) ▲|HD340.02+8.06 (+2.43%) ▲|HON246.77+3.72 (+1.53%) ▲|IBM226.31+2.66 (+1.19%) ▲|INTC91.00+0.80 (+0.89%) ▲|INTU318.39+2.32 (+0.73%) ▲|ISRG375.41+22.08 (+6.25%) ▲|JNJ254.41-1.94 (-0.76%) ▼|JPM352.64+0.85 (+0.24%) ▲|KO86.86-0.73 (-0.83%) ▼|LIN480.46+2.08 (+0.43%) ▲|LLY1,121.36-27.48 (-2.39%) ▼|LMT586.29+3.55 (+0.61%) ▲|LOW212.06+4.25 (+2.05%) ▲|LRCX294.61+1.59 (+0.54%) ▲|MA570.97-2.13 (-0.37%) ▼|MCD265.23-5.41 (-2.00%) ▼|MDLZ61.73-0.58 (-0.93%) ▼|MDT86.68+1.29 (+1.51%) ▲|META590.24+33.53 (+6.02%) ▲|MMM177.23+0.95 (+0.54%) ▲|MO68.26-0.07 (-0.10%) ▼|MRK127.77-2.43 (-1.87%) ▼|MS211.23+0.81 (+0.38%) ▲|MSFT487.65+22.93 (+4.93%) ▲|MU829.50+6.47 (+0.79%) ▲|NEE86.55-0.37 (-0.43%) ▼|NFLX73.33+1.62 (+2.26%) ▲|NKE42.64+0.93 (+2.23%) ▲|NOW114.19+2.96 (+2.66%) ▲|NVDA206.64+5.89 (+2.93%) ▲|ORCL141.85+11.98 (+9.22%) ▲|PEP139.63+0.07 (+0.05%) ▲|PFE25.03+0.02 (+0.08%) ▲|PG144.97+0.48 (+0.33%) ▲|PLTR125.65+2.59 (+2.10%) ▲|PM187.41-3.41 (-1.79%) ▼|QCOM151.57+3.96 (+2.68%) ▲|RTX216.65+1.43 (+0.66%) ▲|SBUX103.37-1.88 (-1.79%) ▼|SCHW105.87+0.63 (+0.60%) ▲|SO92.94-1.60 (-1.69%) ▼|SPG229.16-0.21 (-0.09%) ▼|T23.59+0.34 (+1.46%) ▲|TMO574.03-0.27 (-0.05%) ▼|TMUS177.09+4.38 (+2.54%) ▲|TSLA322.08+10.87 (+3.49%) ▲|TXN269.04-6.70 (-2.43%) ▼|UBER71.61+1.25 (+1.78%) ▲|UNH415.36+0.96 (+0.23%) ▲|UNP291.23-0.90 (-0.31%) ▼|UPS106.87+2.65 (+2.54%) ▲|USB63.94+0.93 (+1.48%) ▲|V365.67-0.46 (-0.13%) ▼|VZ47.36+0.55 (+1.18%) ▲|WFC87.89+1.44 (+1.67%) ▲|WMT110.71-0.49 (-0.44%) ▼|XOM155.06-0.38 (-0.24%) ▼|
29.3 C
New York
Monday, August 3, 2026

Tag: chronic back pain

MUSSO E80 Muse Sees Strong U.S. Sales Following European Breakout and MUSE Design Award Win

MUSSO E80 Muse Ergonomic chair for petite women releasing in USA

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

GRÄFELFING, Germany, June 9, 2026 /PRNewswire/ -- VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsChronic back pain